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IL-18 Regulates Melanoma VLA-4 Integrin Activation
through a Hierarchized Sequence of Inflammatory
Factors
Marı´a Valca´rcel1, Teresa Carrascal2, Olatz Crende2 and Fernando Vidal-Vanaclocha3
Very late antigen-4 (VLA-4) is frequently overexpressed on melanoma cells contributing to inflammation-
dependent metastasis. Melanoma cell adhesion to endothelium via VLA-4–vascular cell adhesion molecule-1
(VCAM-1) interaction was used to study VLA-4 activation during melanoma cell response to inflammation.
Cooperation among major inflammatory mediators was analyzed in melanoma cells exposed to single
inflammatory factors in the presence of inhibitors for other assayed mediators. A stepwise cascade of
hierarchized molecules heterogeneously made and used during melanoma response to IL-18, induced hydrogen
peroxide (H2O2), in turn activating VLA-4 and melanoma cell adhesion to endothelium. The cascade involved
prostaglandin E2 (PGE2) production from melanoma induced by IL-18-dependent tumor necrosis factor-a (TNFa);
next, PGE2-induced IL-1b via vascular endothelial growth factor (VEGF) secretion, which in turn induced VLA-4
activation via cyclooxygenase 2-dependent H2O2. This sequence operated in IL-18R/VLA-4/VEGF-expressing
murine (B16) and human (A375 and 883) melanomas, but not in those without this phenotype. Separation of
active VLA-4-expressing B16 melanoma cells through immobilized VCAM-1 verified their higher IL-18R/TNFR1/
VEGFR2 expression and metastatic growth than inactive VLA-4-expressing cells. However, cooperation among
melanoma cell sub-populations with heterogeneous cytokine receptor levels may occur through VLA-4-
stimulating factors, leading to intratumoral amplification of metastatic potential. Therefore, expression of the
VLA-4-stimulating factor sequence may help to predict melanoma prometastatic risk, and offers therapeutic
targets for metastatic melanoma deactivation through VLA-4 activation blockade.
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INTRODUCTION
Although proinflammatory factors have a supportive role for
host defense and tissue regeneration (Kirsner and Eaglstein,
1993), their increased production during cancer development
often contributes to metastasis (Vidal-Vanaclocha, 2008). This is
remarkable in patients with cutaneous and ocular mela-
nomas, where concentration of major inflammatory factors is
elevated both at tumor sites (Yurkovetsky et al., 2010) and
peripheral blood (Ly et al., 2010), and can further increase
within the tumor microenvironment during tumor progression
(Moretti et al., 1999; Richmond et al., 2009) and administration
of therapeutic agents such as dendritic cell vaccination (Nakai
et al., 2010) and selective V-raf murine sarcoma viral oncogene
homolog B1 inhibitors (Zimmer et al., 2012).
Very late antigen-4 (VLA-4) integrin is frequently over-
expressed on melanoma cells contributing to inflammation-
dependent metastasis. It is well known that host and
tumor-derived proinflammatory factors (Mattei et al., 1994;
Vidal-Vanaclocha et al., 1994), such as IL-1, tumor necrosis
factor-a (TNFa), IL-18, prostaglandin E2 (PGE2), and vascular
endothelial growth factor (VEGF), can stimulate VLA-4-depen-
dent melanoma cell adhesion to endothelium, promoting
experimental hepatic (Mendoza et al., 2004) and bone
marrow metastasis (Valca´rcel et al., 2011). More impor-
tantly, we identified signature genes representing the
response of IL-18R/VEGF/VLA-4-expressing human mela-
noma phenotype to IL-18, and verified their expression
not only in metastatic lesions from patients with melanoma,
but also in their primary cutaneous lesions, suggesting that
inflammation-dependent IL-18R/VEGF/VLA-4-expressing mela-
noma cell phenotype is operating since early stages (Crende
et al., 2013).
Pathophysiological effects of inflammatory factors confer
the tumor microenvironment an important focus for better
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understanding how metastatic behavior of melanoma cells is
regulated. However, experimental melanoma metastasis are
produced by inflammation-dependent and -independent
mechanisms within the same organs (Vidal-Vanaclocha
et al., 1994; Valca´rcel et al., 2011) and different organs
(Anasagasti et al., 1997a), suggesting that not every mela-
noma cells have the capability to respond to prometastatic
effects of inflammation. Not surprisingly, metastatic lesions
with and without IL-18-dependent genes occur in advanced
stage melanoma patients (Crende et al., 2013). Thus, how
melanoma cells respond to the simultaneous action of various
inflammatory molecules acting in the melanoma micro-
environment, and how inflammatory factor-sensing and non-
sensing melanoma cells are cooperating within the complexity
of a melanoma cell community are essential unexplored
aspects that needed to be addressed for better understanding
regulatory pathways of metastatic melanoma and selecting
therapeutic approaches for melanoma patients.
This study analyzes how melanoma cell ability to meta-
stasize via VLA-4-dependent adhesion is regulated by
inflammatory factors within the tumor microenvironment. A
well-established model of melanoma cell adhesion to primary
cultured hepatic sinusoidal endothelium via cytokine-induced
VLA-4–vascular cell adhesion molecule-1 (VCAM-1) inter-
action (Vidal-Vanaclocha et al., 1994, 2000; Anasagasti
et al., 1997b) was used to assess the functional response of
melanoma cells to a broad family of tumor microenviron-
ment proinflammatory factors, including IL-1b, TNFa, IL-18,
VEGF, PGE2, and hydrogen peroxide (H2O2). In order to
analyze potential cooperative actions among these factors,
melanoma cells were exposed to single proinflammatory
factors in the presence of inhibitors for the other assayed
mediators. Finally, B16 melanoma cells with active and inac-
tive VLA-4 were separated through immobilized VCAM-1
substrate and their inflammatory profile and prometastatic
response to inflammatory factors were compared.
We demonstrated that a sequence of hierarchized mole-
cules, heterogeneously made and used during melanoma
cell response to IL-18, induced H2O2, in turn activating
VLA-4 and melanoma cell adhesion to endothelium. Consis-
tent with these data, active VLA-4-expressing melanoma cells
had higher proinflammatory cytokine receptor expression
and metastatic growth than inactive VLA-4-expressing cells,
not using IL-18R/VEGF/VLA-4 pathway. However, coopera-
tion among melanoma cell sub-populations with hetero-
geneous cytokine receptor levels may still occur through
VLA-4-stimulating factors, leading to intratumoral amplification
of melanoma metastasis potential. Therefore, VLA-4-stimulat-
ing factors may help to predict melanoma prometastatic
risk, and per se represent a panel of therapeutic targets for
metastatic phenotype deactivation through VLA-4 inhibition in
melanoma.
RESULTS
Adhesion-stimulating effects of major inflammatory factors
on B16 melanoma cells are VLA-4 integrin dependent
Inflammatory factors of different chemical nature, including
recombinant IL-18, TNFa, VEGF, IL-1b, PGE2, and H2O2,
dose-dependently increased B16 melanoma cell adhesion to
primary cultured murine hepatic sinusoidal endothelium (HSE)
cells. The highest adhesion rates were reached with 10 ng ml–1
of IL-18 and TNFa, 100 ng ml–1 of VEGF and PGE2, 1 ng ml–1
of IL-1b and 10mM of H2O2 (Figure 1a–f). Three B16
melanoma cell sub-populations were operating in this
adhesion model, irrespective of inflammatory factor type:
sub-population endowed with adhesion capacity to HSE in
the absence of any stimulating agent (10–20% cells); sub-
population that became adherent under the effect of inflam-
matory factors (40–60% cells); and sub-population incompe-
tent for HSE cell adhesion (20–40% cells) irrespective of the
adhesion-stimulating agent. As shown in Figure 2a, 10mg ml–1
anti-murine VLA-4 antibody but not same amount of
control IgG completely abrogated every inflammation-
dependent adhesion of B16 melanoma cells, indicating that
their adhesion-stimulating responses were VLA-4 dependent,
irrespective of the inflammatory agent. However, addition of
anti-VLA-4 antibody to basal condition-cultured B16 mela-
noma cells did not alter their adhesion, suggesting that their
constitutively adherent cell sub-population was not using
VLA-4–VCAM-1 interaction for adhesion to HSE.
Integrin activation accounts for inflammation-induced
endothelial adhesion in the B16 melanoma cell sub-population
expressing inactive VLA-4
All B16 melanoma cells expressed VLA-4 under basal culture
conditions (Figure 2b), but only 15% of basal condition-
cultured cells adhered to immobilized recombinant VCAM-1
substrate (Figure 2c), suggesting that the integrin was consti-
tutively expressed as an inactive receptor in the majority of
B16 melanoma cells. However, inflammatory factors remark-
ably increased B16 melanoma cell binding to immobilized
VCAM-1, indicating that VLA-4 activation occurred in a large
cell sub-population. Addition of anti-VLA-4 antibodies to B16
melanoma cells abrogated adhesion-stimulating effects of
inflammatory factors to VCAM-1 substrate (data not shown).
A cell fraction of inflammatory factor-treated B16 melanoma
did not bind to immobilized VCAM-1, indicating it was
unable to activate VLA-4 irrespective of inflammatory factor
type.
Treatment of A375 and 883 human melanoma cells with
IL-18, VEGF, and H2O2 also significantly increased their
adhesion to human umbilical vein endothelial cell (HUVEC)
monolayers and the proadhesive response was completely
abrogated with anti-VLA-4 antibodies (Table 1), whereas the
same inflammatory agents given with and without anti-VLA-4
antibody to non-VLA-4-expressing 526 and 624.28 human
melanoma cell lines, did not significantly alter melanoma cell
adhesion to endothelium (data not shown).
Consistent with sub-population heterogeneity in B16
melanoma with respect to VLA-4 activation by inflammatory
factors, HUTS-4 antibody—which only recognizes active
VLA-4 conformation in human lymphocytes (Luque et al.,
1996)—showed that only 18% A375 melanoma cells had
active VLA-4 conformation in basal culture conditions; that
this percentage increased to 30.5% and 53.8%, following
A375 melanoma cell treatment with VEGF and H2O2,
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respectively; and that similar to B16 melanoma, there was
a sub-population of around 40% A375 melanoma cells
unable to bind to anti-active VLA-4 antibody, irrespective
of inflammatory factor treatment (Figure 2d). Consistent
with these data, non-IL-18R/VEGF/VLA-4-expressing 526 and
624.28 human melanoma cell lines (Crende et al., 2013) did
neither adhere to immobilized VCAM-1 substrate under same
experimental conditions as above (data not shown).
Inflammation induces murine and human melanoma cell
adhesion to endothelium through a hierarchized sequence of
VLA activation-stimulating factors
The time course of inflammatory factor-dependent melanoma
cell adhesion to HSE cells was studied. The highest adhesion
rates were obtained on the sixth hour for IL-18 and TNFa
treatments; on the fourth hour for VEGF and IL-1b treatments;
and after 2 hours treatment for PGE2 and H2O2 (Figure 1g–l).
Therefore, VLA-4 activation-stimulating effects of inflamma-
tory factors on B16 melanoma cells were time dependent, but
if cooperation among inflammatory factors with VLA-4
activation-stimulating effects occurred was unclear. To this
aim, melanoma cells were exposed to single inflammatory
molecules at their most effective times and concentrations, in
combination with specific blocking agents of other assayed
mediators. As shown in Figure 3a, IL-18 significantly (Po0.01)
increased melanoma cell adhesion to HSE by 2.5-fold. How-
ever, the mechanism was completely abrogated by anti-TNFa
antibody, anti-VEGF antibody, IL-1 receptor antagonist, cyclo-
oxygenase 2 (COX-2) inhibitor, and catalase, indicating that
all the blocked inflammatory factors were involved in adhe-
sion-stimulating effects of IL-18.
TNFa also significantly (Po0.01) increased melanoma cell
adhesion to HSE (Figure 3b). In this case, TNFa effect was
blocked by anti-VEGF antibody, IL-1 receptor antagonist,
COX-2 inhibitor, and catalase, but not by anti-IL-18 anti-
body, indicating that the adhesion-stimulating mechanism of
TNFa was IL-18-independent but VEGF/IL-1b/PGE2/H2O2-
dependent.
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Figure 1. Concentration course and time course-dependent proinflammatory factor mediated B16 melanoma cell adhesion to HSE in vitro. (a–f) B16
melanoma cells received increasing concentrations of rmIL-18 and rmTNFa for 6 hours, rmVEGF, and rhIL-1b for 4 hours; rmPGE2 and H2O2 for 2 hours.
(g–l) B16 melanoma cells received 10 ng ml–1 rmIL-18 and rmTNFa, 100 ng ml–1 rmVEGF and rmPGE2, 1 ng ml–1 rhIL-1b and 10mM H2O2. Three separate
experiments were done, each in six replicates (n¼ 18). *Statistically significant (Po0.01) as compared with untreated B16 cells. H2O2, hydrogen peroxide;
HSE, hepatic sinusoidal endothelium; PGE2, prostaglandin E2; rh, recombinant human; rm, recombinant murine; TNFa, tumor necrosis factor-a; VEGF, vascular
endothelial growth factor.
M Valca´rcel et al.
IL-18 and Melanoma VLA-4-Activation
472 Journal of Investigative Dermatology (2014), Volume 134
PGE2 also significantly (Po0.01) increased melanoma cell
adhesion to HSE cells. IL-1b, VEGF, and H2O2-blocking
agents, but not IL-18 and TNFa-neutralizing antibodies, pre-
vented adhesion-stimulating mechanism of PGE2, indicating
that it was IL-18/TNFa-independent, but still IL-1b/VEGF/
H2O2-dependent (Figure 3c). This was consistent with the
remarkable VEGF secretion-stimulating effect of PGE2 on B16
melanoma and with the ability of COX-2 inhibitor to abrogate
VEGF secretion from TNFa-treated B16 melanoma (Valca´rcel
et al., 2011).
VEGF also significantly (Po0.01) increased melanoma cell
adhesion to HSE cells. PGE2, IL-1b, and H2O2-blocking
agents, but not anti-IL-18 and TNFa-neutralizing antibodies,
prevented adhesion-stimulating effect of VEGF (Figure 3d),
indicating that it was IL-18 and TNFa-independent, but IL-1b/
PGE2/H2O2-dependent.
Adhesion-stimulating effect of IL-1b was again blocked
by COX-2 and H2O2 inhibitors, but not by anti-IL-18, anti-
TNFa, and anti-VEGF antibodies, indicating that it was IL-18/
TNFa/VEGF-independent, but still PGE2/H2O2-dependent
(Figure 3e). Consistent with these data, IL-1b increased PGE2
secretion from melanoma cells (data not shown), and COX-2
inhibitor celecoxib, but not anti-VEGF antibodies, abrogated
H2O2 production from IL-1b-treated B16 melanoma cells,
further supporting that besides controlling VEGF production
from TNFa-stimulated B16 melanoma cells, COX-2 was also
regulating H2O2 secretion from IL-1b-stimulated melanoma
cells.
It was also remarkable that pre-treatment of B16 melanoma
cells with catalase before any of the above studied inflamma-
tory factors neutralized their adhesive effects, indicating that
IL-18, TNFa, VEGF, IL-1b, and PGE2 had adhesion-stimulating
effects on B16 melanoma cells through a hierarchized
molecular sequence acting through an extracellular H2O2-
dependent mechanism. None of assayed inflammatory factor
inhibitors significantly altered adhesion of non-stimulated B16
melanoma cells to endothelium (Figure 3f), indicating that
none of studied inflammatory factors were regulating basal
adhesion capacity of melanoma cells.
To further verify that extracellular H2O2 was the last factor
in the VLA-4 activation-stimulating sequence, B16 melanoma
cells were exposed to the same non-toxic low concentrations
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Figure 2. Integrin activation accounts for inflammation induced endothelial adhesion. (a) Effect of anti-VLA-4 antibodies on proinflammatory factor-induced B16
melanoma cell adhesion to HSE. B16 cells received 10 ngml–1 rmIL-18 and rmTNFa (6 hours); 100ngml–1 rmVEGF and 1 ngml–1 rhIL-1b (4 hours); and 100ngml–1
rmPGE2 and 10mM H2O2 (2 hours). B16 cells received 10mg ml
–1 anti-murine VLA-4 antibody or nonspecific IgG 30 minutes before the adhesion assay. Three
separate experiments were done, each in six replicates (n¼ 18). Statistically significant (Po0.01) as compared with untreated cells (*) and to inflammatory factor-
treated cells (**). (b) Flow cytometry on VLA-4 expression by B16 melanoma cells. Cells were labeled with rat anti-mouse VLA-4 antibody (30minutes; 4 1C;
10mg/106 cells) followed by FITC-IgG anti-rat. (c) Proinflammatory factor-treated B16 melanoma cell adhesion assay to immobilize recombinant human VCAM-1.
B16 cells received 1 ng ml–1 rmIL-18 (6 hours), 100 ng ml–1 rmVEGF (4 hours), 1 ng ml–1 IL-1b (4 hours), and 10mM H2O2 (2 hours). Three separate experiments were
done, each in eight replicates (n¼ 18). (*) Statistically significant (Po0.01) as compared with untreated B16 cells. (d) Detection of active conformation VLA-4-
expressing A375 melanoma cells by flow cytometry. Permeabilized A375 melanoma cells were labeled with mouse anti-human active conformation b1 integrin
antibody (5mg/106 cells; 30 minutes; 4 1C) followed by conjugated FITC-IgG anti-mouse. H2O2, hydrogen peroxide; HSE, hepatic sinusoidal endothelium;
PGE2, prostaglandin E2; rh, recombinant human; rm, recombinant murine; TNFa, tumor necrosis factor-a; VCAM-1, vascular cell adhesion molecule-1; VEGF,
vascular endothelial growth factor; VLA-4, very late antigen-4.
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of H2O2, added as above in the presence of specific blocking
agents for all the studied inflammatory factors. As shown in
Figure 3g, none of these blocking agents prevented the
adhesion-stimulating effect of H2O2 on B16 melanoma,
indicating that extracellular H2O2 did not require IL-18, TNFa,
VEGF, IL-1b, and PGE2 effects for inducing melanoma
adhesion. However, all of these inflammatory mediators had
H2O2 production-stimulating effects on B16 melanoma
(Figure 4a) and consistent with adhesion data, specific block-
ing agents for all these inflammatory factors used in same
conditions as in Figure 3, showed that the same sequence of
hierarchized adhesion-stimulating factors was also controlling
H2O2 production by melanoma cells. Therefore, IL-18-
induced B16 melanoma cell adhesion to endothelium through
a cascade of proinflammatory paracrine factors leading to
VLA-4 activation via diffusible H2O2. The sequence first
involved melanoma cell production of PGE2 induced by
IL-18-dependent TNFa; second, melanoma cell production
of IL-1b via PGE2-dependent VEGF effect; and third, mela-
noma VLA-4 activation via COX-2-dependent extracellular
H2O2 induced by IL-1b effect (Figure 4b).
In vitro pre-treatment of A375 and 883 human melanoma
cells with IL-18 increased their proliferation and adhesion to
HUVECs via VEGF-dependent mechanism; and pre-treatment
with either VEGF or H2O2 increased their adhesion to
HUVECs via VLA-4-dependent mechanism (Table 1). Consis-
tent with these findings, they contained a cell sub-population
expressing IL-18 and VEGF receptors and over 40% expressed
VLA-4; they secreted VEGF in response to IL-18; and mouse
treatment with synthetic VLA-4 antagonist (one subcutaneous
dose of 2.5 mg kg–1 on alternate days; Zubia et al., 2005)
decreased experimental hepatic metastasis development of
intrasplenically injected A375 and 883 cells. Therefore,
similar to B16 melanoma, A375 and 883 melanoma cells
used the same sequence of hierarchized inflammatory factors
to activate VLA-4-dependent adhesion.
Cytokine and cytokine receptor-stimulating effects of L-18 in
melanoma
Consistent with above data, reverse transcriptase–PCR
(Figure 5a) and flow cytometry (Figure 5b) showed that IL-18
induced IL-18R, TNFR1, and VEGFR2 gene expression from
B16 melanoma cells, although percent cytokine receptor-
expressing cell fraction was low. In addition, IL-18 also
significantly (Po0.01) increased B16 melanoma cell secretion
of TNFa and VEGF (Figure 5c), indicating that initiation of the
proadhesive melanoma cell response to IL-18-dependent
factors was possible because IL-18R-expressing B16 mela-
noma cells secreted TNFa in response to IL-18. Previously, we
already reported that TNFa induces VEGF production from
TNFR1-expressing B16 melanoma cells via COX-2-dependent
mechanism (Valca´rcel et al., 2011).
Metastatic phenotype of active and inactive VLA-4-expressing
melanoma cell sub-populations
Adhesion to immobilized VCAM-1 substrate was used to
assort basal condition-cultured B16 melanoma cells into
active and inactive VLA-4-expressing sub-populations and
their inflammatory profile and prometastatic response to
inflammatory factors were compared. Active VLA-4-expres-
sing cell sub-population contained 42% IL-18R-expressing
cells, 18% VEGFR2-expressing cells, and 9% TNFR1-expres-
sing cells, whereas inactive VLA-4-expressing cells did not
express these receptors (Figure 5d). Interestingly, the super-
natant from active VLA-4-expressing cells contained higher
levels of VEGF (fivefold) and endothelial cell migration-
stimulating activity (twofold) than inactive VLA-4-express-
ing cells (Figure 5e and f). Moreover, addition of the
Table 1. Functional validation of IL-18R/VEGF/VLA-4
phenotype in human A375 and 883 melanoma cell
lines
Human melanoma cell lines
Parameters A375 883
In vitro proliferation assay1
Untreated 12.3±2.8 16.1±2.3
Anti-VEGF antibody treated 11.4±3.3 16.9±3.5
IL-18 treated 19.6±3.4* 27.4±3.1*
IL-18 plus anti-VEGF antibody treated 10.5±3.1 15.9±4.4
In vitro adhesion assay to HUVEC2
Untreated 20.25±2.56 12.52±2.24
IL-18 treated 35.67±1.79* 25.24±3.29*
IL-18 plus anti-VEGF antibody-treated 22.67±0.96 13.24±1.98
VEGF treated 31.09±3.26* 24.78±2.57*
VEGF plus anti-VLA-4 antibody treated 21.54±1.05 13.06±2.34
H2O2 treated 37.01±4.06* 27.31±4.91*
H2O2 plus anti-VLA-4 antibody treated 19.26±2.75 12.98±2.85
In vitro cytokine receptor expression3
VLA-4 48.05±3.1 42.36±2.3
IL-18R 6.61±1.2 4.83±0.4
Flk-1 10.73±0.8 10.10±1.1
In vitro VEGF secretion4
Untreated 529±28.1 590±20.4
IL-18 treated 1939±37.03* 697±40.6*
In vivo hepatic metastasis growth5
Vehicle-treated mice 28.05±10.14 59.25±39.02
VLA-4-antagonist-treated mice 4.29±2.37* 5.27±1.73*
Abbreviations: Flk-1, fetal liver kinase 1; H2O2, hydrogen peroxide;
HUVEC, human umbilical vein endothelial cell; MTT, 3-[4,5-dimethylthia-
zol-2-yl]-2,5 diphenyl tetrazolium bromide; VEGF, vascular endothelial
growth factor; VLA-4, very late antigen-4.
*Statistically significant (Po0.01) as compared with untreated A375 and
883 melanoma cells.
1As number cells 103 per well by MTT proliferation test, as previously
described (Valca´rcel et al., 2011).
2As percent adhered melanoma cells by plate-scanning fluorimetry.
3As percent expressing cells by flow cytometry.
4As pg per million cells by ELISA.
5As metastasis volume percentage on day 30 after intrasplenic injection of
A375 and 883 cells in vehicle and VLA-4 antagonist-treated nude mice. All
data were expressed as mean values ±SD of three separate experiments.
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same concentration of exogenous H2O2 as in Figure 3g
induced VEGF secretion from active, but not from inactive
VLA-4-expressing cells melanoma cells, which in turn further
increased in vitro migration of primary cultured microvascular
endothelial cells (data not shown). Consistent with these
findings, active VLA-4-expressing cells had a higher (threefold
increase) hepatic metastatic growth than inactive VLA-4-
expressing cells, following their intrasplenic injection in mice
(Figure 5h).
DISCUSSION
Malignant tumors, including cutaneous melanoma (Saini
et al., 1997), can overexpress VLA-4 integrin. However, in
most cases VLA-4 is not operative in the absence of integrin
activation-stimulating agents, such as chemokines (Chigaev
et al., 2001) and integrin-associated proteins, such as CD47
(Barazi et al., 2002). Results from this study demonstrated
that most common mediators of an inflammatory process had
VLA-4 activation-stimulating activity on IL-18R/VEGF/VLA-4-
expressing murine and human melanomas, but not in those
not expressing this phenotype. The integrin activation process
required a stepwise cascade of hierarchized molecules
(Figure 4b) including: TNFa production from IL-18-respondent
melanoma cells; VEGF production from TNFa-respondent
melanoma cells, via COX-2-dependent mechanism; IL-1b pro-
duction from VEGF-respondent melanoma cells; and finally,
VLA-4 activation induced by IL-1b-respondent melanoma
cells, via COX-2-dependent H2O2. Consistent with these
findings, separation of active VLA-4-expressing B16 mela-
noma cells through immobilized VCAM-1 verified their higher
IL-18R/TNFR1/VEGFR2 expression and metastatic growth than
inactive VLA-4-expressing melanoma cells. Expression of the
complete set of VLA-4 activation-stimulating factors and their
receptors at primary melanoma lesions may help to predict
melanoma prometastatic risk, and per se represent a ranked
list of therapeutic targets for metastatic phenotype deactivation
through VLA-4 inhibition in melanoma.
IL-18 was the first mediator of this sequence because it was
the only factor whose VLA-4 activation-stimulating effect was
inhibited by agents neutralizing any other inflammatory factor
from the sequence. TNFa-stimulating effects of IL-18 have also
been reported during host cell activation. For example, IL-18
induced TNFa to stimulate IL-1b and IL-8 production, during
the chemotactic response of T lymphocytes and NK cells
(Puren et al., 1998); IL-18 also induced leukotriene B4
synthesis, during neutrophil recruitment in arthritis (Canetti
et al., 2003) and it has a hierarchic role in the inflammatory
cytokine cascade during arthritis development (Ruth et al.,
2010). Based on immune-stimulating effects of IL-18, exo-
genous IL-18 has been proposed as adjuvant therapy against
melanoma, although its efficacy was limited in patients with
metastatic melanoma (Tarhini et al., 2009). However, IL-18
60
*
**
**
**
** **
*
**
**
**
** **
**
** ** **
**
****
*
* *
40
20
0
—
An
ti-
TN
F
An
ti-
TN
F
An
ti-
TN
F
An
ti-
VE
G
F
rmIL-18-treated
B16M cells
rmTNF-treated
B16M cells
rmVEGF-treated
B16M cells
rmPGE2-treated
B16M cells
rhIL-1β-treated
B16M cells
Untreated
B16M cells
An
ti-
VE
G
F
An
ti-
IL
-1
8
IL
-1
ra
IL
-1
racl
x
cl
x
Ca
ta
la
se
Ca
ta
la
se—
An
ti-
VE
G
F
An
ti-
IL
-1
8
An
ti-
IL
-1
8
IL
-1
ra
IL
-1
ra
IL
-1
racl
x
cl
x
Ca
ta
la
se
Ca
ta
la
se— —
An
ti-
TN
F
An
ti-
VE
G
F
An
ti-
VE
G
F
An
ti-
IL
-1
8
An
ti-
IL
-1
8
cl
x
Ca
ta
la
se
Ca
ta
la
se— —
%
 B
16
M
 a
dh
es
io
n 
to
 H
SE
60
* * * * * *40
30
20
0
— Anti-
IL-18
Anti-
TNF
Untreated B16M H2O2-pre-treated B16M
Anti-
VEGF
IL-1Ra Clx — Anti-
IL-18
Anti-
TNF
Anti-
VEGF
IL-1Ra Clx
%
 B
16
M
 c
el
l
a
dh
es
io
n 
to
 H
SE
a b c d e f
g
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often increases in the blood of cancer patients (Lissoni et al.,
2000) and it has also been associated with disease progression
and metastatic recurrence (Vidal-Vanaclocha et al., 2006).
Consistent with these clinical findings, we recently reported
that high and low IL-18 receptor-expressing human melanoma
significantly varied in their ability to secrete VEGF, to express
VLA-4 and to form experimental metastases in nude mice
(Crende et al., 2013). Moreover, a specific IL-18-dependent
gene expression profile was identified in IL-18-inducible
melanoma cells and some of their overexpressed genes were
identified in primary and metastatic lesions from melanoma
patients (Crende et al., 2013).
The low number of melanoma cells expressing IL-18
receptors in primary and metastatic melanoma lesions may
restrict the effects of IL-18 in the reported VLA-4 activation-
stimulating sequence. However, IL-18 increased melanoma
cell production of a broad spectrum of inflammatory media-
tors and their receptors, which, in turn may serve to recruit
non-IL-18 receptor-expressing melanoma cells into the VLA-4
activation-stimulating cascade. Therefore, paracrine coopera-
tion may operate among melanoma cell sub-populations
expressing some, but not all the mediators and receptors
needed in the VLA-4 activation-stimulating sequence.
Such intratumoral interactions among co-existing cancer cell
sub-populations have been reported in other tumor types
(Jouanneau et al., 1994) and may also contribute to the
enrichment of active VLA-4-expressing melanoma cells in an
inflammatory microenvironment. Moreover, cancer cell res-
ponse to IL-18 is not limited to the reported VLA-4 activation-
stimulating cascade. Stem cell factor (Hue et al., 2005),
thrombospondin-1 (Kim et al., 2006), and transferrin (Park
et al., 2009), are examples of other reported IL-18-stimulating
effects, which are also leading to additional prometastatic
mechanisms (Jung et al., 2006).
H2O2 was at the end of the VLA-4 activation-stimulating
sequence because it was the only diffusible factor whose
proadhesive effect on melanoma cells was not altered by
agents neutralizing any inflammatory factor from the reported
sequence. Previously, it has been reported that ligand binding
of VLA-4 involves a redox modulation contributing to leuko-
cyte trafficking in inflammatory tissues (Liu et al., 2008).
However, direct proadhesive effects of extracelular H2O2
have not been reported in melanoma cells, and its position
at the end of the cascade may also serve to activate VLA-4 in
melanoma cell sub-populations not expressing cytokine
receptors.
Tumor-infiltrating host cells and some prometastatic inflam-
matory microenvironments—as for example those reported in
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liver and bone marrow (Valca´rcel et al., 2011, Vidal-
Vanaclocha, 2011)—may also contribute to the VLA-4
activation-stimulating sequence. For example, IL-18 induced
IL-1b via TNFa production during endotoxin activation of
bone marrow stromal cells, which contributed to the
prometastatic role of inflammation in a bone melanoma
metastasis model (Valca´rcel et al., 2011). In this case, TNFa
production from bone marrow stromal cells also stimulated
VEGF production from melanoma cells, in turn increasing
VLA-4-dependent melanoma cell adhesion to bone marrow
stroma via COX-2. Whatever the mechanism is, the reported
inflammatory factor cascade may represent a functional
axis for host-melanoma cell cooperation, serving to amplify
the metastatic potential of melanoma in the inflammatory
microenvironment generated by melanoma cells and tumor-
infiltrating host cells.
Given the important prometastatic effect of VLA-4 both in
rodent and human melanoma (Martı`n-Padura et al., 1991;
Schlesinger et al., 2010), the hierarchic structure of inflam-
matory mediators with VLA-4 activation-stimulating effects
may have diagnostic and therapeutic implications in
melanoma. From a diagnostic point of view, single cytokine
and cytokine receptor detection may not be enough for
accurately understanding if a given melanoma lesion is or
not regulated by inflammation. According to our results,
specific markers describing the complete VLA-4 activation-
stimulating factor sequence and their receptors are needed for
better assessing prometastatic reactivity of melanoma lesions
under inflammatory conditions. For example, IL-18 and IL-18
receptor expression has been suggested as prognostic factors
at advance stages for many cancer types, including breast,
lung, and gastric cancer (Vidal-Vanaclocha, 2008). However,
at least for melanoma, this may not be enough if other key
interdependent cytokines and cytokine receptors, downstream
IL-18 at the VLA-4-stimulating cascade herein described, are
not studied at the melanoma lesion.
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From a therapeutic point of view, our results show a broad
spectrum of therapeutic targets for metastatic phenotype
deactivation through VLA-4 inhibition in melanoma. How-
ever, their therapeutic value may change according to the
position of the targeted factor at the VLA-4-stimulating
cascade. Therefore, a ranked list of increasingly powerful
inhibitors of VLA-4 activation may also exist along the
reported cascade, with IL-18 inhibitors being the most
restricted, whereas COX-2 inhibitors and antioxidants neutra-
lizing H2O2 being broad-spectrum inhibitors of VLA-4 activa-
tion in melanoma cells.
MATERIALS AND METHODS
Cell lines
HUVECs, murine B16F10, and human A375 melanoma cell lines
were obtained from American Tissue Culture Collection (ATCC,
Manassas, VA). Human 883, 526, and 624.28 melanoma cells were
obtained as previously described (Crende et al., 2013). Cells were
cultured in endotoxin-free RPMI 1640 medium supplemented with
10% fetal bovine serum, 100 units ml–1 penicillin and 100mg ml–1
streptomycin (all tissue culture reagents were from Sigma, St Louis,
MO). HUVECs were also obtained from ATCC and cultured on 0.2%
gelatin-coated tissue culture plate in ATCC endothelial growth
medium.
Cytokines and antibodies
Recombinant mouse IL-18, TNFa, VEGF, IL-1b, and PGE2 were
obtained from R&D Systems (Abingdon, UK). H2O2 and bovine
catalase were obtained from Sigma. Recombinant human IL-1 receptor
antagonist, and anti-murine IL-18, anti-TNFa, and anti-mouse VEGF-
neutralizing antibodies were from R&D Systems. SC-58635
(celecoxib) was provided by Richard A Marks (GD Searle, Skokie, IL).
Isolation and primary culture of hepatic sinusoidal cells
C57BL/6J mice (male, 6–8 weeks old) were obtained from Harlan
Ibe´rica (Barcelona, Spain). Animal housing, their care, and experi-
mental conditions were conducted in conformity with institutional
guidelines, as previously described (Vidal-Vanaclocha et al., 1994).
HSE cells were separated from these mice, identified, and cultured as
previously described (Anasagasti et al., 1997b).
Melanoma cell adhesion assay to endothelial cells and
immobilized VCAM-1 substrate
Murine and human melanoma cells were labeled with 20,70-bis-
(2-carboxyethyl)-5,6-carboxyfluorescein-acetoxymethylester solution
(Invitrogen, Carsbad, CA). Next, 2 105 cells per well melanoma
cells were added to 24-well plate cultured HSE cells (B16) or
HUVECs (A375, 883, 526 and 624.28) for 8 or 60 minutes, respec-
tively. The number of adhered cells was quantified as previously
described (Vidal-Vanaclocha, 1994). For melanoma cell adhesion to
immobilized VCAM-1 substrate, 96-well plates were coated with
0.1mg per well recombinant human VCAM-1 (R&D Systems) at 4 1C
overnight. Nonspecific binding sites on plastic were blocked with
0.5% BSA solution for 2 hours at 37 1C. Then, 5 104 cells per well
20,70-bis-(2-carboxyethyl)-5,6-carboxyfluorescein-labeled melanoma
cells were added for 30 minutes. Next, wells were washed three
times with fresh medium and the number of adhered cells was
determined as above.
Measurement of in vitro H2O2 production by melanoma cells
B16 melanoma cells were incubated with 20mM nonpolar compound
2070-dichlorofluorescein-diacetate (Invitrogen) for 30 minutes at
37 1C. Fluorescence produced by the highly fluorescent compound,
2070-dichlorofluorescein was recorded using a computerized plate-
scanning microfluorimeter (Thermo Labsystems, Fluoroskan Ascent
FL, Waltham, MA) at both 485/22-nm excitation with a 530/25-nm
emission filter as previously reported (Anasagasti et al., 1997b). Non-
2070-dichlorofluorescein-diacetate-incubated cells were used to
determine basal autofluorescence.
Experimental hepatic metastasis assay
C57BL/6J and athymic nude mice (male, 6–8 weeks old) were
obtained from Harlan Ibe´rica and used as described above. Hepatic
metastases were studied on days 12 (for B16 cells) and 30 (for A375
and 883 cells), after intrasplenic injection of 0.1 ml Hank’s balanced
salt solution containing 3 105 murine or 1 106 human melanoma
cells, respectively. Liver metastasis development was quantified as
previously described (Vidal-Vanaclocha et al., 1994).
Isolation and functional assessment of active and inactive
VLA-4-expressing B16 melanoma cells
B16 melanoma cells were incubated for 30 minutes on immobilized
VCAM-1 substrate, prepared as described above. Next, non-adherent
cells (inactive VLA-4-expressing cell sub-population) were collected
by supernatant aspiration. Adherent cells (active VLA-4-expressing
cell sub-population) were collected by VCAM-1–VLA-4 interaction
disruption, after 5-minute incubation in 4 mM EDTA in phosphate-
buffered saline, and collection of detached cells. Next, both cell
sub-populations were cultured until subconfluent growth and their
12-hour-conditioned media was obtained as previously described
(Mendoza et al., 2004) to determine their hepatic endothelial cell
migration-stimulating activity in a previously described HSE cell
chemotactic migration assay (Olaso et al., 2003). The same
cultured melanoma cell sub-populations were next resuspended,
intrasplenically injected in syngeneic mice, and their hepatic
metastasis potentials evaluated and compared as described above.
Quantitative reverse transcriptase–PCR
Total RNAs were extracted using Qiagen RNAase mini kit (Hilden,
Germany) and their concentrations assessed using a NANO DROP
spectrophotometer (ND-1000, Thermo Scientific, Rockford, IL).
Reverse transcription was performed as previously described
(Ma´rquez et al., 2013) and the resulting complementary DNA was
used for reverse transcriptase–quantitative PCR evaluation of relative
expression levels with respect to b-actin (as an internal control). The
sequences (50–30) of used forward and reverse primers were as
follows:
TNFR gene:
Forward primer: CACCGTGACAATCCCCTGTAA
Reverse primer: AGATAACCAGGGGCAACAGC
Product length: 203 bp
IL-18R gene:
Forward primer: AATCAAGCTCCTGGCCTTGC
Reverse primer: GTGAATACAACTTTTTGAGGCACT
Product length: 352 bp
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VEGFR2 gene:
Forward primer: TCTGGACTCTCCCTGCCTAC
Reverse primer: TGATGCAAGGACCATCCCAC
Product length: 231
Gene-specific amplification was performed using ABI-7900HT
RT-qPCR machine (Life technologies, Grand Island, NY) as previously
described (Crende et al., 2013). Reverse transcriptase–quantitative
PCR amplicons were analyzed with gel electrophoresis to confirm
specificity of generated products. Relative expression levels of target
genes were normalized to the geometric mean of the internal control
gene b-actin. Generated data were averaged and expressed in relative
units of normalized expression.
Measurement of TNFa and VEGF concentration
Cytokine concentration was measured in supernatants from B16
melanoma cells using an ELISA kit based on specific murine TNFa
or VEGF monoclonal antibodies (R&D Systems). The concentration of
cytokines was expressed as a function of the total number of cultured
cells.
Flow cytometric analysis
B16 melanoma cells were incubated for 30 minutes at 4 1C with
10mg/106 cells rat anti-mouse VLA-4 antibody (Serotec, Du¨sseldorf,
Germany) and A375M cells with 5mg/106 cells mouse anti-human
active conformation b1-integrin mAb (Chemicon International, Teme-
cula, CA), followed by FITC-conjugated IgG anti-rat and FITC-
conjugated IgG anti-mouse antibody (Zymed, San Francisco, CA)
labeling, respectively, (10mg/106 cells). In other studies, B16 cells
were incubated with 10mg/106 cells goat anti-mouse IL-18Ra antibody
followed by FITC-conjugated anti-goat antibody (10mg/106 cells), or
with 2mg/106 cells TNFR1-PE or 1mg/106 cells VEGFR2-PE (Becton
Dickinson, San Diego, CA) for 30 minutes at 4 1C. Flow cytometry was
performed with a FACS Vantage SE flow cytometer (Becton Dickinson,
Madrid, Spain) by using a wavelength analysis (green-FITC: 530 nm)
after excitation with 488-nm light. Dead cells (o10%) were excluded
from all the analyses using Viaprobe (Becton Dickinson, Spain).
Statistical analyses
Data were expressed as means±SD of three separate experiments. SPPS
statistical software for Microsoft Windows, release 6.0 (Professional
Statistic, Chicago, IL) was used for statistical analyses. Homogeneity of
the variance was tested using the Levene’s test. If the variances were
homogeneous, data were analyzed by using one-way analysis of
variance test, with Bonferroni’s correction analysis for multiple compar-
isons when more than two groups were analyzed. Individual compar-
isons were made with Student’s two-tailed, unpaired t-test (program
Statview 512; Abacus Concepts, for Macintosh, Piscataway, NJ). The
criterion for significance was Po0.01 for all comparisons.
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